Pierre Fabre Group

pierre-fabre.com

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

news image

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More

Business Insights

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

news image

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

news image

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

news image

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More
news image

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More
news image

Business Insights

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More
news image

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More
news image

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More